entertainment -WSS

entertainment

author：comprehensive 2025-09-30 17:27:54 - browse：4514

As a new class of diabetes and obesity medications has soared in popularity, so have the online outlets built to get them in the hands of patients. A new analysis of claims data from Trilliant Health suggests that collectively, telehealth companies — in particular, cash-pay options that market directly to consumers — could account for many of the patients with insurance claims for GLP-1 prescriptions in 2022.

Direct-to-consumer telehealth companies have offered an easier on-ramp for many patients to access prescriptions for a variety of conditions. And since the first GLP-1s were approved for obesity — promising up to 15% weight loss — many of those companies have capitalized on the approvals and surging demand to launch new weight loss businesses. Companies including Calibrate and Ro claim to have reached tens and hundreds of thousands of patients with their weight loss medication programs.

Collectively, their reach may be even larger. The Trilliant Health analysis, conducted on behalf of STAT, offers an early glimpse of the foothold those businesses have gained in GLP-1 prescribing. In a nationwide claims database of more than 300 million patients using both commercial and federal insurance, Trilliant Health found about 3.6 million people with a prescription claim for a GLP-1 — semaglutide, tirzepatide, or injectable liraglutide without insulin — in 2022. To determine where each patient may have gotten those prescriptions, they looked for a medical visit claim within three days of a prescription claim for a GLP-1 — the visit where the script was likely written. But they only found a matching visit for 53% of patients.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Quicker fix for pulse oximeters urged during FDA public meeting

WSS

Novo Nordisk to expand supply of Wegovy for U.S. patients

Woodcock on FDA’s accelerated approval and her next chapter

Medicare to pay more for cardiac rehab in hospital outpatient clinics

How the messy conversation about Dolly changed bioethics

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

Some dementia cases could be undiagnosed liver disease

hotspot

entertainment

focus

Medicare details structure of new drug price negotiation program

ARCH Venture Partners is raising $3 billion for a life sciences fund

Duchenne breakthrough therapy leaves behind pioneering families

'A game

Hollywood unions extend contract negotiations for actors

Cognito secures funding to test medical device for Alzheimer's

Wildfire smoke exposes gaps in outdoor worker protections

The struggle to figure out which patients 'deserve' Wegovy

23andMe had bad news about my health. I wish a person had delivered it

Neurocrine congenital adrenal hyperplasia trial succeeds

leisure time

The real point of Kenneth Smith’s execution by nitrogen gas

What we need to know about Arena Bioworks

Transgender sports debate: Physicians say bans are health issue

Information blocking fines are now fair game in health care

Why the quest to eradicate polio has stumbled

Quicker fix for pulse oximeters urged during FDA public meeting

knowledge

Wikipedia

Wikipedia

leisure time